The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure

OBJECTIVE To evaluate the dose response relationship of moxonidine on plasma concentration of norepinephrine during acute and chronic administration in patients with congestive heart failure (CHF). BACKGROUND Sympathetic activation is increased in heart failure. Moxonidine is an imidazoline ligand a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2000-02, Vol.35 (2), p.398-404
Main Authors: Swedberg, Karl, Bergh, Claes-Håkan, Dickstein, Kenneth, McNay, John, Steinberg, Mitchell
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cardiovascular system
Medical sciences
Miscellaneous
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE To evaluate the dose response relationship of moxonidine on plasma concentration of norepinephrine during acute and chronic administration in patients with congestive heart failure (CHF). BACKGROUND Sympathetic activation is increased in heart failure. Moxonidine is an imidazoline ligand acting on the central nervous system (CNS) receptors to decrease sympathetic activation. METHODS Ninety-seven patients with heart failure and New York Heart Association class II–III symptoms and ejection fraction 8 h). The number of adverse events was similar in the moxonidine and placebo groups. CONCLUSIONS The increased sympathetic activation in CHF can be reduced by moxonidine through CNS inhibition.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(99)00565-3